Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones08:42 ET · Ratings

A Quick Look at Today's Ratings for Aclaris Therapeutics(ACRS.US), With a Forecast Between $3 to $13

Moomoo News08:00 ET · Ratings

Promising Potential of Aclaris Therapeutics' BSI-045B and Pipeline Elevates Buy Rating

TipRanks05:16 ET · Ratings

Aclaris Therapeutics Positioned for Growth With Strategic Acquisition and Promising Pipeline

TipRanks05:16 ET

BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target

Benzinga04:46 ET · Ratings

Piper Sandler: Authorized trade is transformative, significantly raising Aclaris (ACRS.US) target price to $13.

Piper Sandler has upgraded Aclaris' rating from 'neutral' to 'shareholding', and has significantly raised the target price from $3 to $13.

Zhitong Finance01:16 ET